Multiple Regulatory Mechanisms for the *Dictyostelium* **Roco Protein GbpC**^S

Received for publication,October 24, 2011, and in revised form, November 25, 2011 Published, JBC Papers in Press, November 26, 2011, DOI 10.1074/jbc.M111.315739

Arjan Kortholt¹, Wouter N. van Egmond¹, Katarzyna Plak, Leonard Bosgraaf, Ineke Keizer-Gunnink, and Peter J. M. van Haastert²

From the Department of Cell Biochemistry, University of Groningen, Nijenborgh 7, 9747 AG Groningen, The Netherlands

Background: We use GbpC as a model protein of LRRK2, which is defective in Parkinson disease. **Results:** GbpC, like LRRK2, translocates toward the membrane, which is needed for proper functional activity *in vivo*. **Conclusion:** cAMP stimulation induces a cascade leading to activation and, independently, to GRAM-dependent translocation of GbpC toward the cell boundary.

Significance: The experiments provide new insights in the function of GbpC and LRRK2.

GbpC is a multidomain Roco protein in *Dictyostelium***, involved in transduction of intracellular cGMP that is produced by chemotactic signals. We have shown previously that cGMP binding to GbpC induces an intramolecular signaling cascade by activating subsequently the GEF, Ras, and kinase domains. In this study, we report on the cellular localization of GbpC. In resting cells, the protein is present in the cytoplasm, but GbpC rapidly translocates to the cell boundary upon stimulation with the chemoattractant cAMP. Also, during the formation of cellcell streams and osmotic shock, the protein localizes toward the plasma membrane and actin cytoskeleton. The translocation upon cAMP stimulation occurs downstream of heterotrimeric G proteins but is independent of guanylyl cyclases and the previously identified cGMP-induced intramolecular signaling cascade in GbpC. Mutations in the GRAM domain of GbpC lead to disturbed membrane association and inactivation of GbpC function during chemotaxis** *in vivo***. Furthermore, we show that the GRAM domain itself associates with cellular membranes and binds various phospholipids** *in vitro***. Together, the results show that GbpC receives multiple input signals that are both required for functional activity** *in vivo***. cAMP-stimulation induces a cGMP-dependent signaling cascade, leading to activation of kinase activity, and, independently, cAMP induces a GRAM-dependent translocation of GbpC toward the plasma membrane and cell cortex, where it may locally phosphorylate effector proteins, which are needed for proper biological activity.**

Parkinson disease $(PD)^3$ is a neurodegenerative disease that affects more than 5 million people worldwide and one in 100 people over the age of 60. PD is both a chronic and degenerative disorder that is characterized by loss of dopaminergic neurons

in the substantia nigra, associated with the formation of fibrillar aggregates composed of α -synuclein and other proteins (1). Recently, missense mutations in LRRK2 have been linked to autosomal-dominant, late-onset PD (2, 3). LRRK2 is a member of the novel Roco family of complex Ras-like GTPases that have an unique domain architecture. Roco proteins are characterized by the presence of N-terminal leucine-rich repeats (LRR), a Ras-like G-domain called Roc (Ras of complex proteins), followed by a COR domain (C-terminal of Roc) and a kinase domain (4, 5). Next to this general domain composition of the Roco family, individual Roco proteins are found to be combined with a diversity of additional domains. Although the Roco proteins have been studied intensely because of the discovery of missense mutations in LRRK2 segregating with PD, the exact pathogenic role and molecular mechanism of how Roco proteins are activated and function are still not completely understood (6, 7). We have previously used *Dictyostelium* GbpC as model for the complex structure and regulatory mechanism of LRRK2. GbpC, also called Roco1, was originally identified in a bioinformatical screen for molecular targets of the second messenger cGMP and is the founding member of the Roco family of proteins (4, 8, 9). Besides the conserved Roco region, GbpC has an unique regulatory C-terminal region consisting of a Ras Exchange Motif (REM), DEP, CDC25, and two cyclic nucleotide binding domains with a GRAM domain inserted in between (10). Contrary to LRRK2, the cellular function of GbpC has been characterized in detail. GbpC is the only cGMP signal-transducing protein in *Dictyostelium*. cGMP binds with high affinity to its cyclic nucleotide binding domain, and cGMP-mediated GbpC activation is essential for the proper regulation of myosin II during chemotaxis, for cell-cell interactions during multicellular stream formation, and to resist osmotic stress (8, 10–13). Subsequent experiments showed that GbpC contains a complete intramolecular signal transduction pathway. cGMP binding to the cyclic nucleotide binding domain causes activation of the GEF domains, the subsequent GDP/GTP exchange of the Roc-COR domain leading to the activation of the mitogen-activated protein kinase kinase kinase domain, and phosphorylation of downstream targets (14). This intramolecular signaling cascade is essential for GbpC to mediate its signaling function in the cell. Analogous to

<u>5</u> This article contains [supplemental Fig. S1.](http://www.jbc.org/cgi/content/full/M111.315739/DC1)
¹ Both authors contributed equally to this work.

² To whom correspondence should be addressed. Tel.: 31-503634172; Fax: 31-503634165; E-mail: P.J.M.van.haastert@rug.nl.
³ The abbreviations used are: PD, Parkinson disease; LRR, leucine-rich

repeat(s); Roc, Ras of complex proteins; COR, C-terminal of Roc; GEF, guanine nucleotide exchange factor; GRAM, glucosyltransferases, Rab-like GTPase activators, and myotubularins; DEP, Dishevelled, EgI-10, and pleckstrin; RFP, red fluorescent protein; PB, phosphate buffer.

the human Roco protein LRRK2, the LRRs of GbpC are vital for biological activity of GbpC but are not directly involved in the activation of the Roc and kinase domain (15).

Recent data suggest that the subcellular localization of LRRK2 is important for its activity and function. The protein is present both in the cytoplasm and at the membrane, and the membrane-associated LRRK2 dimer most likely represents the physiologically active form of the protein (16). The regulation of membrane association is not well understood but probably includes dimerization, posttranslational modification, and protein-protein interactions (16–18). Here we report that GbpC, like LRRK2, translocates toward the membrane. In resting cells, the protein is present uniformly in the cytoplasm, but during stream formation and under osmotic stress, the protein localizes toward the boundary of the cell. Furthermore, uniform stimulation with the chemoattractant cAMP induces a rapid translocation of the protein toward the cell boundary. To better understand the localization of Roco proteins in the cell, we studied the translocation of GbpC and its function for chemotaxis and cell streaming. Together, our results show that GbpC receives multiple input signals. cAMP stimulation induces a cGMP-dependent signaling cascade leading to kinase activity and, independently, GRAM-dependent translocation of GbpC toward the plasma membrane and cell cortex, which are both needed for proper functional activity *in vivo*.

EXPERIMENTAL PROCEDURES

Strains, Culture Conditions, and Western Blotting—All cells were cultured in HG5 medium (14.3 g/liter oxoid pepton, 7.15 g/liter bacto yeast extract, 1.36 g/liter $\text{Na}_2\text{HPO}_4^*$ 12 H₂O, 0.49 g/liter $\text{KH}_{2}\text{PO}_{4}$, 10 g/liter glucose), and 10 μ g/ml G418 and hygromycin B were added to the medium for selection of cells with extrachromosomal plasmids. Western blotting was done as described previously (14).

Cloning of GbpC Mutants, DEP, and the GRAM Domain— The cloning process of GbpC mutants followed the same strategy as described before (14), with the following notes. Mutations in the GRAM domain of *gbpC* ORF were created using site-directed mutagenesis of the previously described GbpC part 6 and part 8. Novel amplified fragments of *gbpC* cDNA (carrying introduced mutations) were ligated into pBluescript first, and after sequencing, the inserts were subsequently exchanged with part 6 or part 8 of the previously described GbpC parts $6-8$ in the pGemTeasy plasmid (Promega) using unique restriction sites. The last step of the cloning process (fusion of parts $6-8$ with parts $1-5$ in MB74-derived expression plasmids) was done as described previously (14). The primer pair used for expression of the GRAM domain (amino acids 2331–2470) was as follows: C**GGATCC**AAAAAAAT-GACGTCGACTTCACCATTG (the BamHI site is shown in boldface, followed by a Kozak sequence and an underlined start codon) and GGCGGCCGCTTA**ACTAGT** AGCCAATT-TATTTTTG (the SpeI site is shown in boldface). The PCR product was ligated in pBluescript, digested with BamHI/SpeI, and ligated in the BglII/SpeI digested *Dictyostelium* MB74GFP expression plasmid. The plasmids were coelectroporated with monomeric red fluorescent protein MARS (RFP) to *gbpC*-null cells (19).

Fluorescence Microscopy—All fluorescence experiments were carried out on a confocal laser scanning microscope (Zeiss ConfoCor 2-LSM 510 combination setup). For the cAMP-stimulations, vegetative cells were harvested, washed twice in 17 mm phosphate buffer (PB) (pH 6.5), and starved in 6-well plates (Nunc) on non-nutrient-agar (17 mm PB with 1.5% agar) overnight at 8 °C. The next day, cell aggregation was initiated by incubating the plates at room temperature. When cells formed streams, they were harvested and settled in a flow chamber. After 10 min, cells were stimulated with 1 μ m cAMP, and fluorescence was recorded. To analyze GbpC translocation during osmotic stress, cells were resuspended in PB and incubated with 200 mm sorbitol. The line scans and image analyzes were done with ImageJ using a macro that measures the total fluorescence intensity of the cytoplasm in every frame (20). For each strain, 5–20 cells from at least two independent experiments were analyzed.

Phospholipid Filter Binding Assay—Lysates were made by collecting, washing, and resuspending 1.5×10^7 *Dictyostelium* cells in 1 ml of lysis buffer (20 mm HEPES (pH 7.0), 1% Triton, 100 mm KCl, 1 μ g/ml crushed EDTA-free protease inhibitor tablets (Roche)). Samples were left on ice for 60 min, centrifuged (10 min at 4 °C, 14,000 \times *g*), and the supernatants were collected. PIP strip membranes (Echelon) were blocked in blocking solution (3% BSA in TBST (25 mm Tris-HCl, 137 mm NaCl, 5 mm KCl, 0.05% Tween (pH 8.0)) for 1 h at room temperature. Next, the PIP strips were incubated for 1 h with 10 ml of TBST containing 50 μ l of a lysate. After washing three times for 10 min with TBST, anti-GFP antibody (Santa Cruz Biotechnology, Inc., dilution 1:500) in blocking solution was added to the membranes for incubation overnight on a rocking platform at 4 °C. The next day, strips were first washed three times with TBST, and then secondary antibody in blocking solution was added (anti-mouse IgG, Santa Cruz Biotechnology, Inc., dilution 1:2000). Strips were incubated for 1 h at room temperature and subsequently washed three times with TBST. Bound protein was detected using Lumi-Light Plus Western blotting substrate (Roche) according to the supplier's information.

Protein input was visualized with Western blotting using 10 -l of lysate from cells expressing GRAM-GFP and GRAMG2378A-GFP. For direct comparison, both proteins were assayed on PIP strips in parallel and exposed on film together.

Chemotaxis, cGMP-binding Assay, and GTP-agarose Pulldown Assays—Chemotaxis was measured using a small population assay as described before (21). cGMP-binding was measured using a radioisotope binding assay, and GTP-binding was assayed using GTP-coupled agarose beads, both as described before (14).

RESULTS

GbpC Localizes to the Cell Boundary upon cAMP Stimulation and during Streaming—To study the localization of GbpC, we coexpressed GbpC fused at its C-terminal to GFP and monomeric red fluorescent protein MARS (RFP) in *gbpC*-null cells and simultaneously obtained confocal fluorescent images of both markers. The GbpC fusion protein binds cGMP and GTP *in vitro* and restores the *gbpC*-null phenotype (14), suggesting

FIGURE 1. **GbpC translocates to the cell boundary and cell cortex upon cAMP-stimulation and osmotic stress and during cell streaming.** Starved *gbpC*-null cells expressing GbpC-GFP were stimulated with 10-⁶ ^M cAMP. *A*, confocal images at the indicated times before and after cAMP-stimulation. *B*, line-scan images derived of the full image in *A*. Positions of scans are indicated by *arrows* in gray cells before and in black cells 3– 6 s after stimulation. *C*, the decrease of the fluorescence intensity of GbpC-GFP (●) and cytosolic RFP (○) in the cytoplasm, which was analyzed using ImageJ. Data are mean ± S.D. (*n* = 6 cells). *D*, *gbpC*-null cells expressing GbpC-GFP were placed on non-nutrient agar plates and allowed to starve. Confocal images were taken after 6 h of aggregation. *E*, cells expressing GbpC-GFP were exposed to 200 mm sorbitol, and confocal pictures were taken before and after osmotic stress in the presence and absence of actin polymerization inhibitor latrunculin A.

that the GFP tag does not affect correct folding and function of GbpC *in vivo*. In resting cells, GbpC-GFP has a uniform distribution in the cytoplasm. The protein is not enriched at the cell boundary, and it is absent from the nucleus (Fig. 1*A*). No difference in localization was observed between starved and unstarved cells. Global stimulation of starved cells with 10^{-6} M cAMP resulted in a translocation of GbpC-GFP to the cell boundary (Fig. 1*A*). Line scans through the cell reveal a decrease of fluorescence in the cytoplasm with a concomitant increase at the cell boundary (Fig. 1*B*). The kinetics of the cAMP-induced translocation of GbpC-GFP was more accurately monitored by computational analysis of fluorescence intensity depletion in the cytoplasm (Fig. 1*C*). The translocation starts very rapidly after cAMP-stimulation (about 2 s) and is maximal between 4 and 8 s, upon which GbpC gradually returns to the cytoplasm and reaches basal levels after \sim 30 s (Fig. 1*C*). Stimulation with cAMP leads to an average depletion of cytoplasmatic GbpC of $11.4 \pm 4.4\%$ ($n = 19$), whereas the fluorescence intensity of the free RFP marker remains constant, indicating that the observed GbpC translocation is not due to a general change in cell shape or volume.

The biological role of GbpC becomes more important in longer-starved cells and during cell streaming (22, 23). Consistently, whereas GbpC-GFP is cytosolic in starved single cells, GbpC becomes uniformly distributed at the cell boundary when cells make stable head-to-tail cell-cell contacts and are part of streams (Fig. 1*D*).

The Role of the F-actin Cytoskeleton for the Translocation of GbpC to the Cell Cortex—The production of cGMP and activation of GbpC is not only induced by cAMP but also by osmotic stress (11, 24). cGMP production occurs in the order of minutes after osmotic stress compared with a few seconds after cAMP stimulation (12). Therefore, we studied the localization of GbpC-GFP during osmoshock. After incubation with sorbitol,

FIGURE 2. **Expression of mutated GbpC.** *A*, quantification of the maximal decrease of fluorescence intensity in the cytoplasm for GbpC-GFP in the indicated cell strains at 4-8 s after stimulation. Data are mean \pm S.D. *B*, schematic view of the domain architecture of wild-type GbpC and several mutants used in this study. GbpC-G2378A is a point mutant in the GRAM domain, whereas GbpC- Δ GRAM lacks the GRAM domain. The GbpC- Δ LRR mutant misses amino acids 2–311. *C*, alignment of part of the GRAM domain of GbpC with a selection of other GRAM domains. Numbers refer to amino acids. The *asterisk* shows a conserved glycine that was mutated to an alanine to yield the GbpC-G2378A mutant. *Dd*, *Dictyostelium discoideum*; *Hs*, *Homo sapiens*; *Pp*, *Pichia pastoris*. *D*, quantification of the maximal cytoplasmatic fluorescence decrease for mutants in the LRR, GRAM, and DEP domain of GbpC expressed in *gbpC*-null cells. Cells were treated similarly as described in the legend to Fig. 1. *, $p < 0.001$ *versus* RFP control and not significantly different from GbpC-GFP; **, $p < 0.001$ *versus* GbpC-GFP and not significantly different from RFP control (*A* and *D*).

GbpC becomes enriched at the cell boundary and cortex (Fig. 1*E*). Consistent with the slow kinetics of the osmotic response, translocation of GbpC-GFP is maximal about 10 min after addition of sorbitol (data not shown). Because GbpC localization seem to be more fuzzy than only the defined plasma membrane (Fig. 1, *A* and *E*) and because GbpC is an important regulator of myosin II and thus the cytoskeleton (8, 10–13), we investigated

a possible role of the cell cortex in regulating GbpC localization. Therefore, cells were incubated with 15μ M actin-polymerization inhibitor, latrunculin A. Under these conditions, GbpC does not translocate toward the cell boundary upon uniform cAMP stimulation or osmotic stress (Figs. 1*E* and 2*A*), indicating that a functional cytoskeleton is essential for GbpC translocation.

GbpC Translocation Is Regulated by G-protein Signaling but Does Not Depend on Previously Identified Chemotaxis Pathways—In *Dictyostelium*, cAMP binds to the cAMP receptor (cAR1), which results in activation of the heterotrimeric G-protein $G\alpha 2\beta\gamma$ (25). The activated G-protein subunits transduce the signal to the interior of the cell where they activate a complex network of signaling molecules. To assess if GbpC translocation is regulated by this pathway, GbpC-GFP was expressed in cells lacking $g\alpha$ 2. The data show that the translocation of GbpC is completely abrogated (Fig. 2), indicating that localization is regulated by the heterotrimeric G-protein signaling cascade. So far, four signaling pathways have been implicated in chemotaxis: PI3K, TorC2, PLA2, and sGC. Because GbpC binds cGMP with high affinity $(K_d \sim 4 \text{ nm})$ (8) and because cGMP is produced rapidly after cAMP stimulation (26), it could well be that cGMP binding to GbpC regulates the localization of GbpC. To assess this hypothesis, GbpC-GFP was expressed in *gc*-null cells, which lack both guanylyl cyclases and thus cannot produce any cGMP (22). The kinetics and the maximal fluorescence decrease in the cytoplasm were not noticeably disturbed in these cells $(11.7% \pm 3.2%, n = 7)$, suggesting that GbpC translocates independently of guanylyl cyclases and their product cGMP (Fig. 2*A*). This was confirmed by the observation that addition of the membrane-permeable cGMP analog 8-Br-cGMP to cells did not change the distribution of GbpC (data not shown). Next, we tested the involvement of the other signaling pathways by analyzing GbpC translocation in disruption mutants and/or the presence of 20 μ M LY294002 to inhibit PI3K and 90 μ M LY294002 to inhibit PI3K and TORC2 (27) The fluorescence decrease in all mutants is similar to that of wildtype cells (Fig. 2*A*), indicating that none of the signaling enzymes (sGC, PLA2, PI3K, and TorC2) is essential for GbpC translocation.

The GRAM Domain Is Required for GbpC Translocation—In various other proteins, the LRR, DEP, and GRAM domains have been implicated in membrane association (28–31). Therefore, we expressed truncated proteins in which one of these three domains were deleted (Fig. 2*B*). Deletion of the LRR or DEP domain had no effect on the translocation of GbpC, whereas deletion of the GRAM domain abrogated translocation to the cell boundary (Fig. 2*D*).

To further investigate the role of the GRAM domain, we investigated point mutants that could potentially inactivate this domain (Fig. 2*C*). A characteristic glycine is conserved in all GRAM domains. Moreover, this residue was found mutated in myotubularin-related protein 2 (MTMR2), resulting in Charcot-Marie-Tooth disease (28, 29). This G103E mutation causes loss of membrane localization of MTMR2, and a crystal structure of MTMR2 reveals that this residue is positioned in the middle of an important β -sheet (28, 29). We mutated the corresponding glycine to an alanine, resulting in the GRAM mutant GbpC-G2378A (Fig. 2, *B* and*C*). Expression and correct folding of GbpC-G2378A is indicated by the high cGMP-binding activity (data not shown). Upon global cAMP-stimulation with 10^{-6} M cAMP, the GbpC-G2378A mutant showed a strongly disturbed protein translocation to the cell boundary, providing further support that the GRAM domain of GbpC is involved in translocation (Fig. 2*D*).

The GRAM Domain Binds Directly to Cellular Membranes— To further investigate the role of the GRAM domain in membrane targeting of GbpC, we expressed a GFP-tagged GRAM domain in *gbpC*-null cells and determined its localization. The GRAM domain (comprising amino acids 2331–2470) is localized nearly exclusively at the plasma membrane (Fig. 3*A*). This membrane association does not need a functional cytoskeleton but was disrupted when the G2378A mutation was introduced in this protein (Fig. 3*A*). Furthermore, a truncated GRAM domain (missing amino acids 2350–2437) was also cytoplasmatic (data not shown). Together, these results show that the G2378A mutation abolishes the membrane binding capacity of the GRAM domain.

GRAM domains were previously shown to bind phospholipids (31). To determine phospholipid binding potential for the GRAM domain of GbpC, we performed PIP-Strip assays, using lysates from cells that express GRAM-GFP (Fig. 3*B*). In this assay, membrane strips containing spots with various phospholipids are incubated with proteins (Fig. 3*B*). Protein binding to these phospholipids can be detected with antibodies, in this case against GFP to detect GRAM-GFP.We found that GRAM-GFP binds to several phospholipids: mono-PIPs, as well as PI(3,4)P, PI(4,5)P and PI(3,4,5)P are tolerated, but the strongest binding was found for phosphatidic acid and phosphatidylserine, which are the prevailing lipids in *Dictyostelium* (32). In a parallel assay in which the G2378A mutation was introduced, binding to phosphatidic acid and phosphatidylserine was severely reduced, whereas binding to other phospholipids was less disturbed (Fig. 3*B*).

Localization of GbpC Is Critical for Activity in Vivo—Upon starvation, *Dictyostelium* cells enter a developmental program. Cells begin to secrete cAMP and neighboring cells move toward the source of cAMP and relay the signal. Because of the resulting wave of cAMP that travels through the population, cells become polarized, connect to each other in a head-to-tail fashion, and form streams of cells. Cells lacking cGMP or GbpC have a severe streaming defect. These cells show extensive breaks of streams because of reduced cell elongation and the inability to maintain stable head-to-tail cell contacts (13). Whereas re-expression of GbpC in *gbpC-*null cells completely rescues this phenotype (Fig. 4*A*, *left panel*), cells expressing GbpC mutants that lack the GRAM domain or that contains the G2378A mutation still have the *gbpC*-null phenotype (Fig. 4*A*, *right panel*), indicating that the GRAM domain is essential *in vivo*.

Chemotaxis in *Dictyostelium* cells can be monitored by a small-population/drop assay. Cells are placed on nutrient-free agar plates in small drops. Small drops of 10^{-6} M cAMP are placed close to these cells, and chemotactic activity toward cAMP is observed and scored. GbpC plays an important role in chemotaxis together with PI3K, TorC2, and PLA2 (23, 33, 34). The recognition that these parallel pathways mediate the transduction of chemotactic cAMP signals allowed us to develop an assay to specifically analyze the activity of GbpC *in vivo*. In this assay, chemotaxis is measured in the presence of LY294002 (an inhibitor of PI3K) and *p-*bromophenylacyl bromide (an inhibitor of PLA2). Under these circumstances, chemotaxis of 7-h starved cells is critically dependent on guanylyl cyclases and

FIGURE 3. **The GRAM domain of GbpC binds to the plasma membrane.** *A*, confocal fluorescent images were taken from *gbpC*-null cells expressing GRAM-GFP in the absence and presence of latrunculin A or GRAMG2378A-GFP. The results show that GRAM-GFP localizes independently of F-actin at the plasma membrane, whereas the mutant GRAMG2378A-GFP shows a cytoplasmatic distribution. *B*, PIP strips containing spots with various phospholipids were incubated with lysates from cells expressing GRAM-GFP or GRAMG2378A-GFP. Binding of these proteins to phospholipids was visualized using an anti-GFP antibody. For direct comparison, both proteins were assayed on PIP strips in parallel and exposed on film together, and input protein was similar for both proteins.

GbpC. In this assay, AX3 wild-type cells show around 50% chemotaxis, but cells lacking either guanylyl cyclases or GbpC have lost this remaining chemotactic activity. By reintroducing GbpC, chemotaxis is restored to wild-type levels (Fig. 4*B*), which indirectly allows screening for biological activity of GbpC mutants (23). The GbpC- Δ GRAM and GbpC-G2378A mutants were unable to chemotax in this assay, thus highlighting an essential role for the GRAM domain in biological activity of GbpC activity *in vivo*.

We investigated the localization of GbpC during chemotaxis. For careful quantification we coexpressed GbpC-GFP and cytosolic-RFP and obtained images of cells moving toward a pipette releasing cAMP. These images suggest a slight enrichment of GbpC-GFP in the front area of the cell [\(supplemental Fig. S1\)](http://www.jbc.org/cgi/content/full/M111.315739/DC1). We determined the average fluorescent intensity of GbpC-GFP in the cell cortex relative to the intensity in the cytoplasm using cytosolic-RFP as an internal control. The results show that in the cortex at the front of the cell GbpC-GFP is $8.3 \pm 1.4\%$ higher that the levels in the cytoplasm (mean \pm S.E., *n* = 59, *p* < 0.005). The level of GbpC-GFP in the cortex at the side and the rear of the cell is not significantly increased relative to the cytoplasm [\(supplemental Fig. S1\)](http://www.jbc.org/cgi/content/full/M111.315739/DC1).

GbpC Translocation Is Uncoupled from the Intramolecular Signaling Cascade—Correct signaling through the RasGEF, Roc, and mitogen-activated protein kinase kinase kinase domains of GbpC is essential for biological activity of GbpC (14). Because our results suggest that the GRAM is also critical for biological activity of GbpC, we hypothesized that the inactivated GRAM domain could potentially interfere with the

intramolecular signaling cascade in GbpC, thereby inhibiting GbpC activity. One aspect of the intramolecular signaling cascade in GbpC involves cGMP-stimulated GTP binding to (and thus activation of) the Roc domain. This is visualized by pulling down GbpC-GFP with GTP-coupled agarose beads and subsequent Western blotting with a GFP-antibody. Using this assay, we found that the GRAM mutant GbpC-G2378A shows strong cGMP-stimulated GTP-binding activity, implying that a disturbed GRAM domain does not affect (part of) the intramolecular signaling cascade (Fig. 5*A*). We also tested cAMP-stimulated translocation in previously described mutants that are defective in this intramolecular signaling cascade (14). The results (Fig. 5*B*) show that mutants with disturbed RasGEF, Roc, or kinase domains translocate toward the cell boundary as the wild-type protein, indicating that translocation is independent of this signaling cascade. These results demonstrate that protein localization and cGMP-stimulated kinase activity of GbpC are mutually uncoupled processes.

DISCUSSION

The Roco protein LRRK2 has been found to be thus far the most frequent cause of late-onset and idiopathic PD (2, 3). Detailed information about the activation mechanism of LRRK2 is missing, but all known pathogenic mutations in LRRK2 result in decreased GTPase activity and enhanced kinase activity, suggesting a possible PD-related gain of abnormal/toxic function (35– 42). Recently it was shown that Roco proteins belong to the GAD class of molecular switches (G-proteins activated by nucleotide-dependent dimerization) (43, 44).

FIGURE 4. **Development and chemotaxis of GbpC mutants.** *A*, GbpC-GFP and GbpC \triangle GRAM-GFP were expressed in *gbpC*-null cells and starved on nonnutrient agar plates. Pictures of streaming cells were taken after 6 h of starvation. *B*, 7-h starved cells were monitored in a small population assay and
scored for their ability to chemotax toward drops with 10^{–6} м cAMP. Experiments were performed in the presence of 50 μ M LY (PI3K inhibitor) and p-bromophenylacyl bromide (PLA2 inhibitor), which causes chemotaxis to be critically dependent on the cGMP-pathway. The GbpC mutants were expressed in *gbpC*-null cells and compared with the chemotaxis data of AX3 and *gbpC*null cells. The data presented are mean \pm S.E. of at least three independent measurements on different days. *, $p < 0.001$ *versus* gbpC-null and not significantly different from AX3 at $p > 0.05$; **, $p < 0.001$ *versus* AX3 and not significantly different from gbpC-null; ***, significantly less than AX3 at $p < 0.01$ and significantly above gbpC-null at $p < 0.01$.

It has been proposed that the juxtaposition of the G domains of two monomers in the complex across the GTP-binding sites activates the GTPase reaction and thereby regulate the biological function of these proteins. On the basis of the observed effects of PD mutations in LRRK2, it is thought that interaction with other proteins modify the dimer interactions, resulting in decreased GTPases and enhanced kinase activity (43, 44). Understanding how Roco proteins are activated will provide fundamental insights in this important class of proteins, which is also relevant for PD.

The strong and diverse phenotypes of the 11 *Dictyostelium* Roco disruption mutants provides a powerful tool to investigate the activation mechanisms of Roco proteins (9, 14). This resulted in the identification of an intramolecular signaling cascade in GbpC involving cGMP-stimulated RasGEF activity, subsequent Roc activation, and output kinase activity (14). This intramolecular cGMP signaling cascade appears to be essential for cGMP/GbpC-mediated activity during chemotaxis and cell stream formation *in vivo*.

Here, we extended the study by examining the localization of GbpC. We found that localization of GbpC to the cell boundary appears to be a second critical process for activity of GbpC *in vivo*. All mutants that have a disturbed protein translocation upon cAMP stimulation are also strongly disturbed in che-

FIGURE 5. **Protein localization and intramolecular signaling of GbpC are independent processes.** *A*, GbpC-GFP and GbpC-G2378A-GFP were expressed in *gbpC*-null cells. Lysates were prepared, and proteins were pulled down with GTP-agarose beads in the absence or presence of cGMP or GTP, respectively. Bound proteins were visualized on a Western blot analysis using anti-GFP antibodies. cGMP-stimulated GTP binding was still present in the G2378A mutant at comparable levels with the wild-type protein. Representative data for at least three independent experiments on different days are presented. *B*, quantification of the maximal cytoplasmatic fluorescence decrease after cAMP stimulation for GbpC and the previously described GbpC-KinaseDead, GbpC-GefInactive, and GbpC-RocInactive mutants expressed in *gbpC*-null cells. Cells were treated as described in Fig. 1.

motaxis and cell stream formation. Translocation of GbpC to the cell boundary requires the GRAM domain of GbpC and a functional cytoskeleton. Translocation to the cell boundary is inhibited by the F-actin inhibitor latrunculin A. Furthermore, the localization of GbpC after cAMP stimulation, and especially after osmotic shock, strongly resembles the localization of F-actin, suggesting that GbpC may translocate to membrane and the F-actin rich cell cortex. In cells with a deleted or mutated GRAM domain, GbpC no longer translocates to the membrane or cell cortex after stimulation with cAMP or osmotic stress. The N-terminal part (LRR-Roc-COR-kinase) is localized in the cytoplasm, whereas the C-terminal part (GEF-GRAM-cNB) behaves as the full-length protein⁴. The GRAM domain itself associates with the plasma membrane and binds various phospholipids *in vitro*. These experiments suggest that stimulation with cAMP or osmotic stress induces a GRAM-dependent translocation to the plasma membrane and subsequent transient enrichment in the F-actin cytoskeleton that requires the C-terminal part of the protein.

Translocation of GbpC toward the cell boundary occurs independently of cGMP and the intramolecular signaling cascade in GbpC (14). GbpC still translocates toward the cell boundary in mutants that lack either cGMP production or a functional GEF, Roc, or kinase domain, whereas cGMP-stimulated Roc activity in the localization-defective mutants is not

⁴ A. Kortholt, W. N. van Egmond, K. Plak, L. Bosgraaf, I. Keizer-Gunnink, and P. J. M. van Haastert, unpublished data.

FIGURE 6. **Model for the activation of GbpC.** Extracellular cAMP binds to a G-protein-coupled receptor, cAR1, that stimulates a specific G-protein and Ras. A pathway downstream of Ras activation induces transient translocation of GbpC toward the membrane, which may be caused by either activation of the GRAM domain or formation of specific lipids in the membrane (*blue*). The produced cGMP induces an intramolecular signaling cascade involving GEF, Roc-COR, and activation of the kinase domain (*red*). The third activation signal comes from LRR, which are regulating substrate specificity (*green*). GbpC is only active when all three independent processes occur. Active GbpC phosphorylates so far unknown substrates at the cell cortex, which is important for myosin assembly into filaments and, subsequently, chemotaxis and cell streaming.

recognizably different from the activation of the wild-type protein.

Experiments on the role of the LRR domain of Roco proteins suggest that this domain is probably a third critical element for biological activity *in vivo*. Mutants of GbpC that lack this domain exhibit normal cAMP-stimulated translocation toward the membrane (Fig. 2*D*) and have normal cGMP-stimulated activation of the Roc domain (14) but nevertheless cannot support biological activity *in vivo* (14). Similarly in LRRK2, the LRR are essential *in vivo* but not for Roc-activated kinase activity in *vitro* (15).

We propose that the activation mechanism of Roco proteins involves three independent processes (Fig. 6). 1) Regulation of its subcellular localization. Recent studies showed that LRRK2 is present both in the cytoplasm and at the cell boundary, that the fraction of LRRK2 dimer is enriched at the membrane, and that the membrane bound fraction binds GTP more efficiently and has a higher kinase activity than LRRK2 in the cytoplasm (16, 18). Together, these results suggest that the membraneassociated dimer most likely presents the physiologically active form of the protein and that, therefore, regulation of LRRK2 localization is important for its biological function. The exact mechanism and domain of LRRK2 that is required for mem-

brane binding has not been identified. In *Dictyostelium*, the translocation of GbpC toward the cell boundary is critical for proper chemotaxis and cell streaming. The GRAM domain appears to be essential for membrane binding. Translocation of GbpC toward the cell boundary is induced by the chemoattractant cAMP through a signaling cascade that contains the cAMP-receptor cAR1 and heterotrimeric G-proteins but does not depend on one of the previously identified chemotaxis pathways (sGC, PLA2, PI3K, and TorC2). Although the membrane localization of the GRAM domain alone is independent of stimulation or a functional cytoskeleton, GbpC is localized in the cytoplasm before stimulation and translocation is disrupted in the presence of the actin-polymerization inhibitor latrunculin A. This suggests that translocation of GbpC is caused by a cAMP-mediated conformational change in GbpC, thereby resulting in the exposure of the GRAM domain, translocation to the membrane, and, subsequently, binding and phosphorylation of substrates at the cell cortex. Further studies are necessary to identify the upstream regulators and molecular mechanism of this conformational change, but they may well include dimerization and direct protein-protein interactions at the cell cortex. 2) Regulation of kinase activity. Roco proteins belong to the GAD class of molecular switches in which the Roc GTPase is regulated by homodimerization. Roco proteins have a low nucleotide affinity (in the μ м range) and a relative high intrinsic nucleotide exchange rate (43, 44). Therefore, in contrast to Ras GTPases, regulation by GEFs and GAPs is not absolutely necessary for Roco proteins (43, 44). However, to be able to react rapidly on transient responses, additional stimulation by a GEF protein may be required. GbpC differs from the other Roco family members, in the sense that it already contains its own GEF. The cAMP-induced second messenger cGMP binds to GbpC, leading to stimulation of the RasGEF domain, GDP/ GTP exchange at the Roc domain and activation of the output kinase domain. The net outcome of cGMP-binding to GbpC is phosphorylation molecular targets. *iii) Substrate specificity.* The LRR of LRRK2 and *Dictyostelium* GbpC are absolutely essential for activity of the protein *in vivo* (9, 14, 15), but they are not required for cGMP-stimulated Roc activity, nor for protein translocation. The *Dictyostelium* Roco proteins Roco3 (QkgA) and Roco4 are the product of a relatively recent gene duplication in *Dictyostelium*. Nevertheless, gene inactivations result in very different phenotypes (9). By expressing chimera proteins consisting of different combinations of domains from Roco3 and Roco4, it was found that specificity was attributed to the LRR and not to the Roc or kinase domains. Furthermore, On the basis of pull-down assays, the LRR interacts with the kinase domain⁵. These data suggest that LRR mediate input/ output specificity, possibly by binding upstream proteins that activate the Roco protein and/or by selectively binding of the substrate, thereby bringing it in close proximity to the kinase.

Together, our results give new insights in the complex activation mechanism of Roco proteins. Nevertheless, many important questions remain open, for example what are the upstream activators of Roco proteins, what are the output substrates of activated kinase, how does the Roc domain regulates the kinase activity, which role does COR plays in this process, and importantly how do the Parkinson disease-linked muta-

tions alter the interactions between the different domains? We anticipate that addressing these questions in *Dictyostelium* might be instrumental and can thereby contribute to the understanding of the molecular mechanism of LRRK2 activation and how mutations of LRRK2 result in neuronal toxicity.

REFERENCES

- 1. Lees, A. J., Hardy, J., and Revesz, T. (2009) Parkinson's disease. *Lancet* **373,** 2055–2066
- 2. Paisán-Ruíz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., López, de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Carrera, I. M., Pena, A. S., de Silva, R., Lees, A., Martí-Massó, J. F., Pérez-Tur, J., Wood, N. W., and Singleton, A. B. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* **44,** 595–600
- 3. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Carbajal, I. C., Vieregge, P., Asmus, F., Müller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., Wszolek, Z.K., and Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* **44,** 601–607
- 4. Bosgraaf, L., and Van Haastert, P. J. (2003) Roc, a Ras/GTPase domain in complex proteins. *Biochim. Biophys. Acta* **1643,** 5–10
- 5. Marín, I., van Egmond, W. N., and van Haastert, P. J. (2008) The Roco protein family. A functional perspective. *FASEB J.* **22,** 3103–3110
- 6. Cookson, M. R., and Bandmann, O. (2010) Parkinson's disease. Insights from pathways. *Hum. Mol. Genet.* **19,** R21-R27
- 7. Cookson, M. R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. *Nat. Rev. Neurosci.* **11,** 791–797
- 8. Bosgraaf, L., Russcher, H., Smith, J. L., Wessels, D., Soll, D. R., and Van Haastert, P. J. (2002) A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in *Dictyostelium*. *EMBO J.* **21,** 4560–4570
- 9. van Egmond, W. N., and van Haastert, P. J. (2010) Characterization of the Roco protein family in *Dictyostelium discoideum*. *Eukaryot. Cell* **9,** 751–761
- 10. Goldberg, J. M., Bosgraaf, L., Van Haastert, P. J., and Smith, J. L. (2002) Identification of four candidate cGMP targets in *Dictyostelium*. *Proc. Natl. Acad. Sci. U.S.A.* **99,** 6749–6754
- 11. Araki, T., van Egmond, W. N., van Haastert, P. J., and Williams, J. G. (2010) Dual regulation of a *Dictyostelium* STAT by cGMP and Ca2+ signalling. *J. Cell Sci.* **123,** 837–841
- 12. Kuwayama, H., Ecke, M., Gerisch, G., and Van Haastert, P. J. (1996) Protection against osmotic stress by cGMP-mediated myosin phosphorylation. *Science* **271,** 207–209
- 13. Veltman, D. M., and van Haastert, P. J. (2008) The role of cGMP and the rear of the cell in *Dictyostelium* chemotaxis and cell streaming. *J. Cell Sci.* **121,** 120–127
- 14. van Egmond, W. N., Kortholt, A., Plak, K., Bosgraaf, L., Bosgraaf, S., Keizer-Gunnink, I., and van Haastert, P. J. (2008) Intramolecular activation mechanism of the *Dictyostelium* LRRK2 homolog Roco protein GbpC. *J. Biol. Chem.* **283,** 30412–30420
- 15. Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carrì, M. T., and Barone, P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. *Hum. Mol. Genet.* **16,** 1319–1326
- 16. Berger, Z., Smith, K. A., and Lavoie, M. J. (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. *Biochemistry* **49,** 5511–5523
- 17. Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., and Alessi, D. R. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. *Biochem. J.* **430,** 393–404
- 18. Sen, S., Webber, P. J., and West, A. B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. *J. Biol. Chem.* **284,** 36346–36356
- 19. Bosgraaf, L., Keizer-Gunnink, I., and Van Haastert, P. J. (2008) PI3-kinase

signaling contributes to orientation in shallow gradients and enhances speed in steep chemoattractant gradients. *J. Cell Sci.* **121,** 3589–3597

- 20. Bosgraaf, L., van Haastert, P. J., and Bretschneider, T. (2009) Analysis of cell movement by simultaneous quantification of local membrane displacement and fluorescent intensities using Quimp2. *Cell Motil. Cytoskeleton* **66,** 156–165
- 21. Konijn, T. M. (1970) Microbiological assay of cyclic 3 ,5 -AMP. *Experientia* **26,** 367–369
- 22. Veltman, D. M., and Van Haastert, P. J. (2006) Guanylyl cyclase protein and cGMP product independently control front and back of chemotaxing *Dictyostelium* cells. *Mol. Biol. Cell* **17,** 3921–3929
- 23. Veltman, D. M., Keizer-Gunnik, I., and Van Haastert, P. J. (2008) Four key signaling pathways mediating chemotaxis in *Dictyostelium discoideum*. *J. Cell Biol.* **180,** 747–753
- 24. Araki, T., Tsujioka, M., Abe, T., Fukuzawa, M., Meima, M., Schaap, P., Morio, T., Urushihara, H., Katoh, M., Maeda, M., Tanaka, Y., Takeuchi, I., and Williams, J. G. (2003) A STAT-regulated, stress-induced signalling pathway in *Dictyostelium*. *J. Cell Sci.* **116,** 2907–2915
- 25. Van Haastert, P. J., and Devreotes, P. N. (2004) Chemotaxis. Signalling the way forward. *Nat. Rev. Mol. Cell Biol.* **5,** 626–634
- 26. Roelofs, J., and Van Haastert, P. J. (2002) Characterization of two unusual guanylyl cyclases from *Dictyostelium*. *J. Biol. Chem.* **277,** 9167–9174
- 27. Liao, X. H., Majithia, A., Huang, X., and Kimmel, A. R. (2008) Growth control via TOR kinase signaling, an intracellular sensor of amino acid and energy availability, with cross-talk potential to proline metabolism.*Amino Acids* **35,** 761–770
- 28. Begley, M. J., Taylor, G. S., Kim, S. A., Veine, D. M., Dixon, J. E., and Stuckey, J. A. (2003) Crystal structure of a phosphoinositide phosphatase, MTMR2. Insights into myotubular myopathy and Charcot-Marie-Tooth syndrome. *Mol. Cell* **12,** 1391–1402
- 29. Berger, P., Schaffitzel, C., Berger, I., Ban, N., and Suter, U. (2003) Membrane association of myotubularin-related protein 2 is mediated by a pleckstrin homology-GRAM domain and a coiled-coil dimerization module. *Proc. Natl. Acad. Sci. U.S.A.* **100,** 12177–12182
- 30. de Rooij, J., Rehmann, H., van Triest, M., Cool, R. H., Wittinghofer, A., and Bos, J. L. (2000) Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. *J. Biol. Chem.* **275,** 20829–20836
- 31. Tsujita, K., Itoh, T., Ijuin, T., Yamamoto, A., Shisheva, A., Laporte, J., and Takenawa, T. (2004) Myotubularin regulates the function of the late endosome through the gram domain-phosphatidylinositol 3,5-bisphosphate interaction. *J. Biol. Chem.* **279,** 13817–13824
- 32. Weeks, G., and Herring, F. G. (1980) The lipid composition and membrane fluidity of *Dictyostelium discoideum* plasma membranes at various stages during differentiation. *J. Lipid Res.* **21,** 681–686
- 33. Kamimura, Y., Xiong, Y., Iglesias, P. A., Hoeller, O., Bolourani, P., and Devreotes, P. N. (2008) PIP3-independent activation of TorC2 and PKB at the cell's leading edge mediates chemotaxis. *Curr. Biol.* **18,** 1034–1043
- 34. Chen, L., Iijima, M., Tang, M., Landree, M. A., Huang, Y. E., Xiong, Y., Iglesias, P. A., and Devreotes, P. N. (2007) PLA2 and PI3K/PTEN pathways act in parallel to mediate chemotaxis. *Dev. Cell* **12,** 603–614
- 35. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D. W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., and Cookson, M. R. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiol. Dis.* **23,** 329–341
- 36. Guo, L., Gandhi, P. N., Wang, W., Petersen, R. B., Wilson-Delfosse, A. L., and Chen, S. G. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. *Exp. Cell Res.* **313,** 3658–3670
- 37. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T., and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. *Biochemistry* **46,** 1380–1388
- 38. Lewis, P. A., Greggio, E., Beilina, A., Jain, S., Baker, A., and Cookson, M. R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. *Biochem. Biophys. Res. Commun.* **357,** 668–671
- 39. Li, X., Tan, Y. C., Poulose, S., Olanow, C. W., Huang, X. Y., and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase

activity that is altered in familial Parkinson's disease R1441C/G mutants. *J. Neurochem.* **103,** 238–247

- 40. Luzón-Toro, B., Rubio de la Torre, E., Delgado, A., Pérez-Tur, J., and Hilfiker, S. (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. *Hum. Mol. Genet.* **16,** 2031–2039
- 41. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc. Natl. Acad. Sci. U.S.A.* **102,** 16842–16847
- 42. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D.,

Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L., and Dawson, T. M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTPbinding and kinase activities to neuronal toxicity. *Hum. Mol. Genet.* **16,** 223–232

- 43. Gasper, R., Meyer, S., Gotthardt, K., Sirajuddin, M., and Wittinghofer, A. (2009) It takes two to tango. Regulation of G proteins by dimerization. *Nat. Rev. Mol. Cell Biol.* **10,** 423–429
- 44. Gotthardt, K., Weyand, M., Kortholt, A., Van Haastert, P. J., and Wittinghofer, A. (2008) Structure of the Roc-COR domain tandem of *C. tepidum*, a prokaryotic homologue of the human LRRK2 Parkinson kinase. *EMBO J.* **27,** 2239–2249

